These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The lonidamine derivative H2-gamendazole reduces cyst formation in polycystic kidney disease. Sundar SV; Zhou JX; Magenheimer BS; Reif GA; Wallace DP; Georg GI; Jakkaraj SR; Tash JS; Yu ASL; Li X; Calvet JP Am J Physiol Renal Physiol; 2022 Oct; 323(4):F492-F506. PubMed ID: 35979967 [TBL] [Abstract][Full Text] [Related]
5. [Tolvaptan, a vasopressin V Yamada Y; Fujiki H; Mizuguchi H; Takeshita Y; Hattori K; Ohmoto K; Aihara M; Nagano K; Isakari Y; Yamamoto M; Yamamura Y Nihon Yakurigaku Zasshi; 2022; 157(4):254-260. PubMed ID: 35781456 [TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase Isoform Regulation of Cell Proliferation and Fluid Secretion in Autosomal Dominant Polycystic Kidney Disease. Pinto CS; Raman A; Reif GA; Magenheimer BS; White C; Calvet JP; Wallace DP J Am Soc Nephrol; 2016 Apr; 27(4):1124-34. PubMed ID: 26289612 [TBL] [Abstract][Full Text] [Related]
7. Sulfonylurea-sensitive K(+) transport is involved in Cl(-) secretion and cyst trowth by cultured ADPKD cells. Sullivan LP; Wallace DP; Gover T; Welling PA; Yamaguchi T; Maser R; Eppler JW; Grantham JJ J Am Soc Nephrol; 2002 Nov; 13(11):2619-27. PubMed ID: 12397031 [TBL] [Abstract][Full Text] [Related]
8. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children? Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745 [TBL] [Abstract][Full Text] [Related]
9. Endogenous concentrations of ouabain act as a cofactor to stimulate fluid secretion and cyst growth of in vitro ADPKD models via cAMP and EGFR-Src-MEK pathways. Jansson K; Nguyen AN; Magenheimer BS; Reif GA; Aramadhaka LR; Bello-Reuss E; Wallace DP; Calvet JP; Blanco G Am J Physiol Renal Physiol; 2012 Oct; 303(7):F982-90. PubMed ID: 22859406 [TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study. Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426 [TBL] [Abstract][Full Text] [Related]
19. Effect of tolvaptan on renal handling of water and sodium, GFR and central hemodynamics in autosomal dominant polycystic kidney disease during inhibition of the nitric oxide system: a randomized, placebo-controlled, double blind, crossover study. Al Therwani S; Malmberg MES; Rosenbaek JB; Bech JN; Pedersen EB BMC Nephrol; 2017 Aug; 18(1):268. PubMed ID: 28810844 [TBL] [Abstract][Full Text] [Related]
20. The relationship between cell proliferation, Cl- secretion, and renal cyst growth: a study using CFTR inhibitors. Li H; Findlay IA; Sheppard DN Kidney Int; 2004 Nov; 66(5):1926-38. PubMed ID: 15496164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]